Hepion Pharma surges after fatty liver disease drug meets trial goals

Hepion Pharmaceuticals

22/05/2023 18:05

(Updates)
    ** Shares of drug developer Hepion Pharmaceuticals  HEPA.O 
rise ~73% to $15.33 premarket 
    ** Stock set for its biggest daily pct rise since 2015, if
gains hold 
    ** Says its experimental drug to treat a type of fatty liver
disease, non-alcoholic steatohepatitis (NASH), met the main and
secondary goals of a mid-stage study 
    ** The drug, rencofilstat, helped improve some measures of
liver impairment in the trial 
    ** Including session's gain, HEPA shares have risen ~155%
YTD 

 (Reporting by Manas Mishra and Raghav Mahobe)
 ((Manas.Mishra@thomsonreuters.com;
www.twitter.com/Manaswrites15;))